The JI
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     
 

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wu, Q.
Right arrow Articles by Sontheimer, R. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, Q.
Right arrow Articles by Sontheimer, R. D.
The Journal of Immunology, 2004, 172: 1630-1636.
Copyright © 2004 by The American Association of Immunologists

Blockade of Lymphotoxin Signaling Inhibits the Clinical Expression of Murine Graft-versus-Host Skin Disease1

Qiang Wu*, Yang-Xin Fu{dagger} and Richard D. Sontheimer2,*

* Department of Dermatology, University of Iowa Roy J. and Lucille A. Carver College of Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA 52242; and {dagger} Department of Pathology and Committee on Immunology, University of Chicago, Chicago, IL 60637


   Abstract
Top
 Abstract
Introduction
 Materials and Methods
 Results
 Discussion
 References
 
Adhesion molecules are essential for the recruitment of T cells into the skin during the development of graft-vs-host skin disease (GVHSD). However, the mechanisms responsible for the regulation of expression of cutaneous adhesion molecules in this setting are still poorly understood. In this study we blocked lymphotoxin (LT) signaling in a murine model of minor histocompatibility Ag system mismatch GVHSD by using an LT{beta} receptor-Ig fusion protein (LT{beta}R-Ig). The recipient mice treated with control human Ig developed clinically apparent, severe skin lesions. However, none of the mice treated with LT{beta}R-Ig developed clinical skin disease. The expression of ICAM-1 in cutaneous tissue was also much lower in mice treated with LT{beta}R-Ig than in mice treated with human Ig. Thus, the inhibition of LT signaling via LT{beta}R-Ig treatment appears to be capable of markedly ameliorating the development of GVHSD, possibly by inhibiting the expression of adhesion molecules.


   Introduction
Top
 Abstract
 Introduction
Materials and Methods
 Results
 Discussion
 References
 
Early/acute murine graft-vs-host skin disease (GVHSD)3 can serve as an experimental model for the human lichenoid tissue reaction, a histopathological pattern that is common to human skin diseases such as lupus erythematosus, dermatomyositis, lichen planus, as well as the early/acute phase of human GVHSD (1). In prior studies, our laboratory examined a murine early GVHSD model resulting from minor histocompatibility Ag system (mHA) mismatch (2). Using this model, we previously demonstrated that the infiltration of T cells into the skin is essential for the epidermal basal cell injury pattern that is present in early murine GVHSD lesions (2). Other studies have also implicated activated T cells as the primary effector cell type in the lichenoid tissue reaction (1, 3).

Adhesion molecule-ligand interactions are essential for the regulation of T cell migration into cutaneous tissues (4, 5, 6, 7, 8). Some studies have shown that the expression of adhesion molecules is significantly up-regulated in the injured skin induced by GVHD (6, 7). However, the molecular mechanism(s) responsible for the enhanced expression of adhesion molecules on dermal microvessels and epidermal keratinocytes in this setting is poorly understood.

TNF-{alpha}, a member of the TNF superfamily, plays a crucial enhancing role in the expression of adhesion molecules on dermal microvessels during the development of lichenoid cutaneous lesions (5, 8). However, blockade of the TNF pathway with anti-TNF Abs has been unable to completely prevent the expression of GVHSD, suggesting that other inflammatory cytokines could be involved in the pathogenesis of lichenoid cutaneous lesions.

LT, another member of the TNF superfamily, is expressed as a soluble homotrimer (LT{alpha}3) or as a membrane-bound heterotrimer (LT{alpha}1{beta}2; mLT) on activated lymphocytes (9, 10). LT{alpha}3 interacts with and signals through TNF receptors I and II and displays similar biological functions as TNF-{alpha} in the inflammatory activity (9, 10). However, mLT binds to and signals through the LT{beta} receptor (LT{beta}R). The interaction between mLT and its receptor is essential for the development of lymphoid tissues and lymphocyte compartmentalization in the spleen as well as for the migration of dendritic cells into lymphoid tissues via controlling the expression of chemokines and adhesion molecules (9, 10, 11, 12). Blockade of the mLT-LT{beta}R interaction in nonobese diabetic mice not only effectively prevents the onset of diabetes at the initial phase, but also inhibits the development of diabetes at the stage of insulitis (13). We speculate that LT may be required to up-regulate chemokines and/or adhesion molecules to create the local microenvironment that attracts autoreactive T cells.

We, therefore, questioned whether mLT signaling might play a role in the clinical expression of GVHSD. To answer this question, in the present study mice receiving mHA mismatch bone marrow (BM) and spleen cells were treated with LT{beta}R-Ig. We found that the blockade of mLT signaling by LT{beta}R-Ig treatment could completely inhibit the development of clinically evident murine GVHSD skin lesions. This effect could be mediated by the down-regulation of chemokines and adhesion molecules necessary for T cell homing to the skin.


   Materials and Methods
Top
 Abstract
 Introduction
 Materials and Methods
Results
 Discussion
 References
 
Mice

Female C57BL/6J (B6, H-2b) and LP/J (H-2b) mice were purchased from The Jackson Laboratory (Bar Harbor, ME) and housed in the animal care facility at University of Iowa. Both murine strains have multiple minor histocompatibility locus differences. For this study all mice were female, and donor animals were 7–12 wk of age; recipients were 6–8 wk of age.

Reagents

LT{beta}R-Ig was generated according to the method described previously (11, 13). The following anti-mouse Abs were used for immunohistochemistry: purified anti-CD4 (rat Ig2a, clone H129.19), purified anti-CD8 (rat Ig2a, clone 53-6.7), and purified hamster anti-ICAM-1(Armenian hamster IgG, clone 3E2). All Abs were obtained from BD PharMingen (San Diego, CA).

GVHSD induction

The murine GVHSD employed was previously described by our laboratory in detail (2). In brief, BM cells were obtained by flushing the marrow cavities of the femurs and tibiae of donor mice with PBS. A single-cell suspension of donor BM and spleen cells was filtered through sterile nylon mesh and resuspended in PBS. Recipient B6 mice were irradiated with 10 Gy from a 137Cs source. Six hours later, the mice were injected i.v. via the retrobulbar venous plexus with 4 x 106 splenocytes and 2 x 106 BM cells from LP/J or B6 mice in 0.2 ml of PBS. In some experiments recipient mice were injected i.v. with 75 µg of LT{beta}R-Ig or control human Ig in 200 µl of PBS on days 0 and 7 after BM and spleen cell transplantation.

Evaluation of GVHD disease

Body weight. B6 recipient animals in all groups were weighed weekly throughout the study. A body weight loss of >1 g of initial weight was considered significant. Results were shown by average body weight change (grams).

Gross skin disease. B6 recipient animals were observed weekly for the development of clinical skin lesions. Mice first developed clinically evident skin lesions 28 days after transplantation; photographs of representative, clinically evident skin changes were obtained at various time points thereafter.

Histopathology of skin disease. Posterior neck skin biopsies were obtained on days 14, 28, and 40 after transfusion and were preserved in methanol, followed by embedding in paraffin. Tissue sections (7 µm) were prepared and stained with H&E. A numerical scoring system was used to grade the patterns of the observed histopathological changes. The scoring system consisted of five levels (from 0 to 4) based on the degree of infiltration of mononuclear cells and thickening of the epidermis and dermis. The levels of scoring included: 0, no signs of inflammation; 1, low density mononuclear cell infiltration in dermis/epidermis; 2, high density of mononuclear cell infiltration in dermis/epidermis; 3, widening/thickening of epidermis; and 4, widening/thickening of the dermis and decrease in number of hair follicles. These histopathological patterns generally reflected the severity of the associated clinical changes observed.

Demonstration of epidermal keratinocyte apoptosis

TUNEL staining was conducted according to the manufacturer’s instructions (Roche, Indianapolis, IN) on skin sections using an in situ cell death detection kit employing a fluorescence readout signal. Briefly, posterior neck skin biopsies were embedded in OCT compound (Miles-Yeda, Elkhart, IN), and frozen at -70°C. Frozen sections (7 µm) were prepared and fixed in 4% paraformaldehyde. The sections were incubated with proteinase K (20 µg/ml) for 30 min at 37°C and then incubated with 0.1% Triton X-100 (in 0.1% sodium citrate) for 2 min on ice. After washing in PBS, the sections were incubated with TUNEL reaction mixture for 60 min at 37°C. Sections were then observed under a fluorescence microscope. The number of TUNEL-positive cells in epidermis per linear millimeter was evaluated using ImageJ software (Research Service Branch, National Institute of Mental Health, National Institutes of Health, Bethesda, MD).

Immunohistochemistry or immunofluorescence

Posterior neck skin biopsies were fixed in IHC ZinC fixative (BD PharMingen) and embedded in paraffin for immunohistochemistry or immunofluorescence. Methanol-treated sections (7 µm) were stained with H&E by standard methods for evaluation by light microscopy. For T cell demonstrations, 7-µm IHC ZinC-fixed sections were sequentially incubated with 1) rat anti-CD4 or anti-CD8 at a dilution of 1/100, 2) biotinylated mouse anti-rat IgM at a dilution of 1/200, or 3) FITC-conjugated anti-biotin clone BN-34 at a dilution of 1/150 (Sigma-Aldrich, St. Louis, MO). For ICAM-1 demonstration, sections were incubated with 1) hamster anti-ICAM-1 at a dilution of 1/120, 2) biotinylated mouse anti-hamster IgG mixture at a dilution of 1/200, or 3) alkaline phosphatase-conjugated streptavidin. HRP-mediated color development was performed using the 3,3'-diaminobenzidine substrate kit (BD PharMingen). The numbers of ICAM-1-positive capillaries per square millimeter in cutaneous tissue and of ICAM-1-positive keratinocytes per linear millimeter were evaluated using ImageJ software. In addition, the intensity of the positive capillaries was evaluated using a grading scale of three levels based on the staining intense: +, weak staining; ++, medium staining; and +++, strong staining.

Statistical analysis

All data were expressed as the mean and SD. The statistical significance of difference between means was determined using two-tailed Student’s t tests. Differences were considered significant at p < 0.05.


   Results
Top
 Abstract
 Introduction
 Materials and Methods
 Results
Discussion
 References
 
Skin lesions expressed in the LP/J>B6 GVHD murine model

The mHA mismatch LP/J>B6 GVHSD model that was employed in the present study has been previously described (2). In this model, recipient B6 mice develop clinical and histopathological evidence of progressive cutaneous GVHD disease (Figs. 1 and 2A). Recipient mice developed the earliest clinical skin lesions, including scruffiness and hair loss over the posterior aspect of the neck, on day 28 after transfusion. Skin biopsy at that time revealed severe mononuclear cell infiltration and increased overall skin thickness (Fig. 2, D and G). By day 40 after transfusion, variable combinations of alopecia, blistering, erosion, crusting, and hyperkeratosis were observed initially, starting on the posterior aspect of the neck and then extending gradually to the face and abdomen (Fig. 1A). Skin biopsy on day 40 after transfusion displayed severe mononuclear cell infiltration, compressed and atrophic hair follicles, and increased overall skin thickness (Fig. 1, B and C). B6>B6 syngeneic control mice did not develop clinically evident skin lesions.



View larger version (48K):
[in this window]
[in a new window]
  		FIGURE 1. Skin lesions resulting from LP/J:B6 mHA mismatch. Lethally irradiated B6 recipients were transplanted with LP/J donor BM and spleen cells. A, By day 40 after transfusion, the majority of recipient mice showed clinical skin lesions, including alopecia and scales over posterior neck and face. B and C, Biopsies of the posterior neck skin on day 40 after transfusion were obtained and fixed in methanol. Sections (7 µm) were stained with H&E. Original magnification: B, x200; and C, x600.

 


View larger version (56K):
[in this window]
[in a new window]
  		FIGURE 2. LT{beta}R-Ig treatment effectively blocks the appearance of skin lesions. Lethally irradiated B6 recipients were transplanted with B6 BM and spleen cells (syngeneic controls) or LP/J donor BM and spleen cells (experimental). On days 0 and 7, experimental recipients (n = 9) transplanted with LP/J donor BM and spleen cells were given i.v. injections of 75 µg of LT{beta}R-Ig in 200 µl of PBS or 75 µg of human Ig in 200 µl of PBS (n = 11). Syngeneic recipients (n = 6) were injected i.v. with 200 µl of PBS. A, Approximately 55% of the LP/J>B6 and human Ig-treated mice showed clinical skin lesions, and administration of LT{beta}R-Ig could block the development of such skin lesions. B, LP/J>B6 and human Ig-treated mice exhibited clinically obvious, severe skin lesions. In contrast, LP/J>B6 and LT{beta}R-Ig-treated animals showed no visible skin changes, nor did B6>B6 syngeneic controls. C–E and F–H, Biopsies of the posterior neck skin on day 28 after transfusion from B6>B6 controls (C and F) and LP/J>B6 and human Ig-treated mice (D and G) and LP/J>B6 and LT{beta}R-Ig-treated mice (E and H). Skin biopsies were fixed in methanol, and 7-µm sections were stained with H&E. Original magnification: C–E, x100; and F–H, x600. I, Measurement of dermis and epidermal thickness in these H&E stained sections. Panel J shows the results of the histopathological scoring system described in Materials and Methods. K, Changes in body weight of the animals in the various experimental and control groups over time. All results indicated in Fig. 2 were representative of three independent experiments.

 
LT{beta}R-Ig treatment inhibits cutaneous GVHD and weight loss

Recent studies, revealed that LT signaling plays an important role in the pathogenesis of autoimmune diabetes and experimental autoimmune myasthenia (13, 14, 15). Blockade of LT signaling could prevent CD8-positive T cell-mediated intestinal allograft rejection (16). Thus, we hypothesized that the LT-LT{beta}R pathway might be involved in the development of GVHSD.

To test this hypothesis, B6 recipient mice were treated with 75 µg of LT{beta}R-Ig on days 0 and 10 after LP/J BM and spleen cell transfusion. By 40 days after transfusion, 55% of control mice treated with human Ig had developed clinically obvious, severe skin lesions consisting of varying elements of blistering, erosion, crusting, hyperkeratosis, and alopecia on the face, ears, neck, and abdomen (Figs. 1A and 2, A and B). However, recipient B6 mice treated with LT{beta}R-Ig and syngeneic B6>B6 control mice had not developed clinical skin lesions at this same time point (Fig. 2, A and B). Compared with B6>B6 mice (Fig. 2, C, F, and I), posterior neck skin biopsies from human Ig-treated control animals revealed an ~200% increase in epidermal thickness and an ~70% increase in dermal thickness due largely to prominent mononuclear cell infiltration on day 28 after transfusion (Fig. 2, D, G, and I). Skin biopsies of mice treated with LT{beta}R-Ig at the same point in time demonstrated only low levels of mononuclear cell infiltration and normal skin thickness (Fig. 2, E, H, and I). The skin pathology score was much higher in control mice treated with human Ig than in B6>B6 mice, and there was no significant difference between mice treated with LT{beta}R-Ig and B6>B6 mice (Fig. 2J).

Although recipient mice in all groups displayed transient body weight loss by days 7–14 due to irradiation toxicity, only mice treated with human Ig showed significant weight loss resulting from GVHD on day 49 after transfusion. In contrast, mice treated with LT{beta}R-Ig and B6>B6 control mice returned to normal body weight after undergoing transient weight loss (Fig. 2K). Similar findings were obtained in two additional replicate experiments. These data suggest that LT{beta}R-Ig treatment can effectively block the clinical expression of murine GVHSD.

LT{beta}R-Ig treatment inhibits T cell homing to skin

Our laboratory has previously demonstrated that T lymphocytes are the primary cellular effectors of epidermal basal cell injury that occurs in the LP/J>B6 model of early murine GVHD skin lesions (2). To determine whether LT{beta}R-Ig treatment could inhibit the infiltration of T cells into the skin in this model, immunofluorescence analysis was conducted on posterior neck skin biopsy sections on day 14 after transplantation in all groups. At the time of biopsy, severe T cell infiltration was detected in the dermis and epidermis in human Ig-treated animals, but no significant difference were detected in the numbers of CD4+ and CD8+ T cells (Fig. 3, A and B). In contrast, very few T cells were detected in the skin of the LT{beta}R-Ig treated animals (Fig. 3, C and D). These data suggest that LT{beta}R-Ig treatment can prevent the infiltration of T cells into skin, suggesting a role for LT signaling in the regulation of T cell recruitment that could be important to the development of GVHD skin lesions.



View larger version (50K):
[in this window]
[in a new window]
  		FIGURE 3. LT{beta}R-Ig treatment inhibits the recruitment of T cell into the cutaneous tissues. Biopsies of the posterior neck skin on day 14 after transfusion were fixed in IHC ZinC fixative, and 7-µm sections were stained with anti-CD4 or anti-CD8 Ab (indicated in green), then examined and photographed by immunofluorescence microscopy. A and B, LP/J>B6 and human Ig-treated mice (n = 3); C and D, LP/J>B6 and LT{beta}R-Ig-treated mice (n = 3). Original magnification, x400. Representative fields were shown. Similar results were observed in two additional replicate experiments.

 
LT{beta}R-Ig treatment inhibits epidermal keratinocyte apoptosis

Keratinocyte apoptosis can be induced by autoreactive T cells and local inflammatory cytokines (8, 17, 18, 19). The presence of apoptotic keratinocytes is a useful early diagnostic criterion for GVHD. Fig. 3 indicates that blockage of mLT signaling can dramatically inhibit T cell recruitment into the skin. We therefore sought to determine whether LT{beta}R-Ig treatment could prevent keratinocyte apoptosis by inhibiting T cell infiltration into skin.

Apoptotic keratinocytes were identified in situ by the TUNEL technique on sections from skin biopsies taken on day 14 after transplantation. More apoptotic cells (green) were present in epidermis and hair follicles of the skin from human Ig-treated control animals than in LT{beta}R-Ig-treated animals (p = 0.007; Fig. 4). These data suggest that mLT signaling might be involved in the induction of keratinocyte apoptosis in part by regulating the recruitment of skin-homing T cells into skin.



View larger version (33K):
[in this window]
[in a new window]
  		FIGURE 4. LT{beta}R-Ig treatment inhibits epidermal and dermal cellular apoptosis. Biopsies of the posterior neck skin on day 14 after transfusion were embedded in OCT compound, and frozen sections (7 µm) were prepared and fixed in 4% paraformaldehyde. Apoptotic cells were detected on these sections in situ by the fluorescence TUNEL technique, as indicated in green. A, LP/J>B6 and human Ig-treated mice (n = 3). B, LP/J>B6 and LT{beta}R-Ig-treated mice (n = 3). Original magnification, x600. Curved lines indicate the junction between epidermis (above line) and the dermis (below line). Similar results were observed in two additional replicate experiments. C, Using these TUNEL-staining sections, the numbers of TUNEL epidermal-positive cells per linear millimeter were evaluated as described in Materials and Methods. Results were presented as the mean ± SD for each group (n = 3).

 
LT{beta}R-Ig treatment prevents the expression of adhesion molecules

Enhanced expression of adhesion molecules on the surface of dermal endothelial cells is crucial for autoreactive T cell attachment and migration through the endothelial barrier into cutaneous tissues during the development of autoimmune skin diseases (4, 5, 6, 7). LT singling has been shown to regulate the migration of lymphocytes and dendritic cells via the regulation of adhesion molecule expression in secondary lymphoid organs and inflamed tissues (12, 13, 20, 21). In the present study we have demonstrated that the blockade of the LT-LT{beta}R pathway can markedly decrease the extravasation of T cells into cutaneous tissue. To address a mechanism that might be responsible for this effect, we next examined the expression of adhesion molecules during the development of GVHSD disease in this model.

ICAM-1 was examined by immunohistochemistry on sections from skin biopsies taken on days 14 and 28 after transplantation. Strong expression of ICAM-1 on dermal microvascular endothelium was observed in day 14 skin biopsies in control mice treated with human Ig (Fig. 5B), whereas only weak expression was observed in mice treated with LT{beta}R-Ig (Fig. 5A). The number of ICAM-1-positive dermal capillaries was also found to be greater in day 14 skin biopsies of mice treated with human Ig than in mice treated with LT{beta}R-Ig (p = 0.007) (data not shown). The expression of ICAM-1 on epidermal keratinocytes was detected at much higher levels in skin biopsies from mice treated with human Ig than in those from mice treated with LT{beta}R-Ig (Fig. 5, C–F) on day 28 after transfusion. The positive keratinocytes in skin biopsies from mice treated with human Ig extended through the full thickness of the epidermis with increased staining intensity (Fig. 5, D and F). Compared with mice treated with LT{beta}R-Ig, the numbers of ICAM-1-expressing epidermal keratinocytes were significantly increased in day 28 skin biopsies from mice treated with human Ig (p = 0.005; Fig. 5G). These data suggest that the prevention of infiltration of skin-homing T cells into the cutaneous tissues by LT{beta}R-Ig treatment might have been associated with the down-regulation of adhesion molecule expression.



View larger version (72K):
[in this window]
[in a new window]
  		FIGURE 5. LT{beta}R-Ig treatment down-regulates the expression of ICAM-1 in cutaneous tissues. Biopsies of the posterior neck skin taken on day 14 or 28 after transplantation were fixed in IHC ZinC fixative, and 7-mm sections were stained with anti-ICAM-1 Ab by immunohistochemistry, as indicated in brown. A, C, and E. LP/J>B6 and LT{beta}R-Ig-treated mice. B, D, and F, LP/J>B6 and human Ig-treated mice. Biopsies on day 14 after transplantation showed the expression of ICAM-1 on endothelium (A and B; n = 3 in each group). Biopsies on day 28 after transplantation showed the expression of ICAM-1 on keratinocytes (arrow; C–F; n = 3 in each group). Original magnification: A–D, x100; E and F, x200; and insets, x600. G, The numbers of ICAM-1-positive cells in the epidermis per linear millimeter on 28 day after transplantation were evaluated as described in Materials and Methods. Results were displayed as the mean ± SD for each group (n = 3). All results presented in Fig. 5 were representative of three independent experiments.

 

   Discussion
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
References
 
In the present study we have demonstrated that lethally irradiated B6 mice receiving LP/J BM and spleen cells develop clinically obvious skin lesions with a histopathology consistent with that of early/acute GVHD. Moreover, there was a significant loss of body weight appearing 10 days after the recipient mice first developed clinically obvious skin lesions. These data suggest that the earliest and predominant target of attack in the mHA mismatch murine GVHD model employed in this study is cutaneous tissue.

Interestingly, the appearance of such skin lesions could be completely blocked by the administration of LT{beta}R-Ig. Such treatment appeared to inhibit the extravasation of T cells into and down-regulate ICAM-1 expression within cutaneous tissue. The administration of LT{beta}R-Ig has also been shown by others (22) to inhibit the expression of GVHD, as reflected by an increase in survival and a reversal of weight loss via blocking the activation of donor effector T cells. However, neither that study nor our present one has fully excluded the possibility that LT{beta}R-Ig treatment might have also decreased donor cell engraftment and thereby moderated the intensity of the resulting GVHD reaction. This issue will be addressed in future studies in our laboratory.

Local primary inflammatory cytokines such as TNF-{alpha} and IL-1 can play important roles in the induction of keratinocyte destruction via directly damaging local tissues and attracting inflammatory cells (5, 8, 17, 18, 23). Within the skin, these cytokines are thought to be produced predominately by keratinocytes and activated T cells (8, 17, 18). LT{alpha}3, defined as having similar biological activity as TNF-{alpha}, is also found to be expressed on activated keratinocytes and T cells in skin tissue, suggesting that the interaction of LT{alpha}3 singling may also be involved in the induction of keratinocyte destruction (24). The prevention of GVHSD by LT{beta}R-Ig treatment described in the present study might involve the inhibition of inflammatory cytokines such as LT{alpha}3 and TNF-{alpha} produced by both keratinocytes and T cells via the blockade of the LT signaling pathway. It will be interesting to examine the LT family member-mediated inflammatory cytokine levels and distribution in this model.

It has been demonstrated that T cells produce epidermal basal keratinocyte injury by cell-mediated cytotoxicity and the production of inflammatory cytokines during the pathogenesis of human disorders that produce a lichenoid tissue reaction such as GVHSD, lupus erythematosus, dermatomyositis, and lichen planus (1, 2, 3). The impairment of T cell recruitment to the skin could prevent the development of such skin inflammation (25). Our previous work has shown that blockade of LT-mediated autoactive T cell infiltration into the pancreas could inhibit the onset of diabetes mellitus in NOD mice (13). The results described in this study further demonstrate that the blockade of LT signaling can effectively inhibit the infiltration of skin-homing T cells into cutaneous tissues, suggesting that LT-mediated recruitment of T cells into skin might be at least partially responsible for the development of GVHSD and possibly other lichenoid tissue reaction skin disorders.

T cells programmed to home to cutaneous tissue undergoing immune-mediated inflammation must undergo several critical steps, including attachment to the endothelium and migration through the endothelial barrier. The interactions between adhesion molecules and their ligands are critical steps for the attachment of T cells to the endothelium of cutaneous microvessels. Therefore, better understanding the mechanisms regulating the expression of adhesion molecules is highly relevant to immunotherapy for human skin diseases displaying the lichenoid tissue reaction. ICAM-1 expression has been found to be increased in GVHD, and blocking ICAM-1 expression can ameliorate the development of GVHD (25, 26).

Our results in the present study suggest that blockade of the LT-LT{beta}R signaling pathway can down-regulate the expression of ICAM-1 on endothelial cells in the dermis. Regulation by members of the TNF superfamily of the expression of adhesion molecules has been well established (8, 27, 28). Both LT{alpha}3 and TNF-{alpha} can up-regulate the expression of adhesion molecules such as ICAM-1 in vitro (8). This adhesion molecule also plays an important role in T cell homing to the skin. The mLT signaling pathway has been shown to be involved in the expression of adhesion molecules in secondary lymphoid organs (20, 21). Inhibition of this signaling pathway by administration of both LT{beta}R-Ig and anti-LT{beta} Ab can efficiently block the expression of mucosal cell adhesion molecule-1 in the spleen (20, 21). We have previously shown that LT{beta}R-Ig treatment can decrease the homing of dendritic cells to the spleen (11). Therefore, the down-regulation of adhesion molecule expression by LT{beta}R-Ig treatment might be responsible for the inhibition of T cell infiltration into cutaneous tissue. Some work has shown that the expression of ICAM-1 on keratinocytes is increased in the lesional skin of GVHD (6, 7, 29, 30). This high level of ICAM-1 expression is thought to facilitate T cell-mediated target destruction by the attachment of T cells to keratinocytes (7, 29, 30). Interestingly, in the present study we found that the level of ICAM-1 expression on keratinocytes was significantly lower in transplanted mice treated with human Ig than in transplanted mice treated with LT{beta}R-Ig. The down-regulation of ICAM-1 expression on keratinocytes resulting from LT{beta}R-Ig treatment might be very important in protecting keratinocytes from T cell-mediated destruction. Taken together, our experiment suggests that LT-mediated adhesion molecule expression may be important in the development of GVHSD.


   Acknowledgments
 
We thank Dr. Gina Schatteman for providing facilities support in carrying out the histopathological studies in this project.


   Footnotes
 
1 This work was supported in part by a 2001 Dermatology Foundation Research Fellowship Award (to Q.W.). In addition, R.D.S. holds the John S. Strauss Endowed Chair in Dermatology. This work was also supported by start-up funding from the University of Iowa Roy J. and Lucille A. Carver College of Medicine, a departmental endowment from the Herzog Foundation, and the Joseph Marshall Family of Morningside, IA. Preparation of this manuscript was supported in part by National Institutes of Health (National Institute of Arthritis and Musculoskeletal and Skin Diseases) Grant AR19101. Its contents are solely the responsibility of the author and do not necessarily represent the official views of the National Institute of Arthritis and Musculoskeletal and Skin Diseases. Back

2 Address correspondence and reprint requests to Dr. Richard D. Sontheimer, Department of Dermatology, University of Iowa Carver College of Medicine/University of Iowa Hospitals and Clinics, 200 Hawkins Drive, 2045BT-1, Iowa City, IA 52242-1090. E-mail address: richard-sontheimer{at}uiowa.edu Back

3 Abbreviations used in this paper: GVHSD, graft-vs-host skin disease; BM, bone marrow; LT, lymphotoxin; LT{beta}R, lymphotoxin {beta} receptor; LT{beta}R-Ig, LT{beta} receptor-Fc Ig fusion protein; mHA, minor histocompatibility Ag system; mLT, membrane-bound LT. Back

Received for publication May 28, 2003. Accepted for publication November 19, 2003.


   References
Top
 Abstract
 Introduction
 Materials and Methods
 Results
 Discussion
 References
 

  1. Shiohara, T., N. Moriya, M. Nagashima. 1988. The lichenoid tissue reaction: a new concept of pathogenesis. Int. J. Dermatol. 27:365.[Medline]
  2. Charley, M. R., J. L. Bangert, B. L. Hamilton, J. N. Gilliam, R. D. Sontheimer. 1983. Murine graft-host skin disease: a chronologic and quantitative analysis of two histologic patterns. J. Invest. Dermatol. 81:412.[Medline]
  3. Shiohara, T., N. Moriya, C. Gotoh, J. Hayakawa, M. Nagashima, K. Saizawa, H. Ishikawa. 1990. Loss of epidermal integrity by T cell-mediated attack induces long-term local resistance to subsequent attack. I. Induction of resistance correlates with increases in Thy-1+ epidermal cell numbers. J. Exp. Med. 171:1027.[Abstract/Free Full Text]
  4. Pober, J. S., M. S. Kluger, J. S. Schechner. 2001. Human endothelial cell presentation of antigen and the homing of memory/effector T cells to skin. Ann. NY Acad. Sci. 941:12.[Abstract/Free Full Text]
  5. Santamaria Babi, L. F., R. Moser, M. T. Perez Soler, L. J. Picker, K. Blaser, C. Hauser. 1995. Migration of skin-homing T cells across cytokine-activated human endothelial cell layers involves interaction of the cutaneous lymphocyte-associated antigen (CLA), the very late antigen-4 (VLA-4), and the lymphocyte function-associated antigen-1 (LFA-1). J. Immunol. 154:1543.[Abstract]
  6. Osawa, J., K. Kitamura, S. Saito, Z. Ikezawa, H. Nakajima. 1994. Immunohistochemical study of graft-versus-host reaction (GVHR)-type drug eruptions. J. Dermatol. 21:25.[Medline]
  7. Norton, J., J. P. Sloane. 1991. ICAM-1 expression on epidermal keratinocytes in cutaneous graft-versus-host disease. Transplantation 51:1203.[Medline]
  8. Orteu, C. H., R. D. Sontheimer, J. P. Dutz. 2001. The pathophysiology of photosensitivity in lupus erythematosus. Photodermatol. Photoimmunol. Photomed. 17:95.[Medline]
  9. Fu, Y. X., H. Molina, M. Matsumoto, G. Huang, J. Min, D. D. Chaplin. 1997. Lymphotoxin-{alpha} (LT{alpha}) supports development of splenic follicular structure that is required for IgG responses. J. Exp. Med. 185:2111.[Abstract/Free Full Text]
  10. Matsumoto, M., Y. X. Fu, H. Molina, D. D. Chaplin. 1997. Lymphotoxin-{alpha}-deficient and TNF receptor-I-deficient mice define developmental and functional characteristics of germinal centers. Immunol. Rev. 156:137.[Medline]
  11. Wu, Q., Y. Wang, J. Wang, E. O. Hedgeman, J. L. Browning, Y. X. Fu. 1999. The requirement of membrane lymphotoxin for the presence of dendritic cells in lymphoid tissues. J. Exp. Med. 190:629.[Abstract/Free Full Text]
  12. Fu, Y. X., D. D. Chaplin. 1999. Development and maturation of secondary lymphoid tissue. Annu. Rev. Immunol. 17:399.[Medline]
  13. Wu, Q., B. Salomon, M. Chen, Y. Wang, L. M. Hoffman, J. A. Bluestone, Y. X. Fu. 2001. Reversal of spontaneous autoimmune insulitis in nonobese diabetic mice by soluble lymphotoxin receptor. J. Exp. Med. 193:1327.[Abstract/Free Full Text]
  14. Goluszko, E., S. H. Munson, C. C. Chao, M. Vadeboncoeur, J. Toma, H. O. McDevitt. 2001. A critical role for lymphtotoxin-beta receptor in the development of diabetes in nonobese diabetic mice. J. Exp. Med. 193:1333.[Abstract/Free Full Text]
  15. Goluszko, E., P. Hjelmstrom, C. Deng, M. Poussin, N. H. Ruddle, P. Christadoss. 2001. Lymphotoxin-{alpha} deficiency completely projects C57BL/6 mice from developing clinical experimental autoimmune myasthenia gravis. J. Neuroimmunol. 113:109.[Medline]
  16. Guo, Z., J. Wang, L. Meng, Q. Wu, O. Kim, J. Hart, G. He, P. Zhou, J. R. Thistlethwaite, Jr, M. L. Alegre, et al 2001. Cutting edge: membrane lymphotoxin regulates CD8+ T cell-mediated intestinal allograft rejection. J. Immunol. 167:4796.[Abstract/Free Full Text]
  17. Akdis, C. A., M. Akdis, A. Trautmann, K. Blaser. 2000. Immune regulation in atopic dermatitis. Curr. Opin. Immunol. 12:641.[Medline]
  18. Akdis, M., A. Trautmann, S. Klunker, K. Blaser, C. A. Akdis. 2001. Cytokine network and dysregulated apoptosis in atopic dermatitis. Acta Odontol. Scand. 59:178.[Medline]
  19. Schwarz, A., R. Bhardwaj, Y. Aragane, K. Mahnke, H. Riemann, D. Metze, T. A. Luger, T. Schwarz. 1995. Ultraviolet-B-induced apoptosis of keratinocytes: evidence for partial involvement of tumor necrosis factor-{alpha} in the formation of sunburn cells. J. Invest. Dermatol. 104:922.[Medline]
  20. Mackay, F., G. R. Majeau, P. Lawton, P. S. Hochman, J. L. Browning. 1997. Lymphotoxin but not tumor necrosis factor functions to maintain splenic architecture and humoral responsiveness in adult mice. Eur. J. Immunol. 27:2033.[Medline]
  21. Mackay, F., J. L. Browning. 1998. Turning off follicular dendritic cells. Nature 395:26.[Medline]
  22. Tamada, K., K. Shimozaki, A. I. Chapoval, G. Zhu, G. Sica, D. Flies, T. Boone, H. Hsu, Y. X. Fu, S. Nagata, et al 2000. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat. Med. 6:283.[Medline]
  23. Groves, R. W., H. Mizutani, J. D. Kieffer, T. S. Kupper. 1995. Inflammatory skin disease in transgenic mice that express high levels of interleukin 1 alpha in basal epidermis. Proc. Natl. Acad. Sci. USA 92:11874.[Abstract/Free Full Text]
  24. Middel, P., U. Lippert, K. M. Hummel, H. P. Bertsch, M. Artuc, S. Schweyer, H. J. Radzun. 2000. Expression of lymphotoxin-{alpha} by keratinocytes: a further mediator for the lichenoid reaction. Pathobiology 68:291.[Medline]
  25. Blazar, B. R., P. A. Taylor, A. Panosksltsis-Mortari, G. S. Gray, D. A. Vallera. 1995. Coblockade of the LFA1:ICAM and CD28/CTLA4:B7 pathways is a highly effective means of preventing acute lethal graft-versus-host disease induced by fully major histocompatibility complex-disparate donor grafts. Blood 85:2607.[Abstract/Free Full Text]
  26. Howell, C. D., J. Li, W. Chen. 1999. Role of intercellular adhesion molecule-1 and lymphocyte function-associated antigen-1 during nonsuppurative destructive cholangitis in a mouse graft-versus-host disease model. Hepatology 29:766.[Medline]
  27. Cuff, C. A., R. Sacca, N. H. Ruddle. 1999. Differential induction of adhesion molecule and chemokine expression by LT{alpha}3 and Lt{alpha}{beta} in inflammation elucidates potential mechanisms of mesenteric and peripheral lymph node development. J. Immunol. 162:5965.[Abstract/Free Full Text]
  28. Fan, J., R. S. Frey, A. Rahman, A. B. Malik. 2002. Role of neutrophil NADPH oxidase in the mechanism of tumor necrosis factor-{alpha}-induced NF-{kappa}B activation and intercellular adhesion moledule-1 expression in endothelial cells. J. Biol. Chem. 277:3404.[Abstract/Free Full Text]
  29. Teraki, Y., N. Moriya, T. Shiohara. 1994. Drug-induced expression of intercellular adhesion molecule-1 on lesional keratinocytes in fixed drug eruption. Am. J. Pathol. 145:550.[Abstract]
  30. Shen, N., P. French, D. Guyotat, M. French, D. Fierce, P. A. Bryon, M. Dechavanne. 1994. Expression of adhesion molecules in endothelial cells during allogeneic bone marrow transplantation. Eur. J. Haematol. 52:296.[Medline]



This article has been cited by other articles:


Home page
 BloodHome page
Y. Xu, A. S. Flies, D. B. Flies, G. Zhu, S. Anand, S. J. Flies, H. Xu, R. A. Anders, W. W. Hancock, L. Chen, et al.
Selective targeting of the LIGHT-HVEM costimulatory system for the treatment of graft-versus-host disease
Blood, May 1, 2007; 109(9): 4097 - 4104.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wu, Q.
Right arrow Articles by Sontheimer, R. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wu, Q.
Right arrow Articles by Sontheimer, R. D.

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS